JPRN-jRCT2080221817未知3 期
ong-term Extension Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 435
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients who are considered by the investigator eligible for the present study with no significant safety concerns
- •- Patients who are fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study
排除标准
- •- Patients who are planning pregnancy for the expected duration of the study
- •- Patients who are otherwise considered ineligible for the study by the investigator
研究者
相似试验
已完成
3 期
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With SchizophreniaSchizophreniaNCT01614912Sumitomo Pharma Co., Ltd.284
招募中
3 期
ong-term Study of SM-13496 (Lurasidone Hydrochloride) in Adolescent Subjects with SchizophreniaSchizophreniaJPRN-jRCT2011210024Yabuuchi Kazuki51
进行中（未招募）
1 期
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with SchizophreniaSchizophreniaEUCTR2016-000061-23-PLSunovion Pharmaceuticals Inc.289
进行中（未招募）
1 期
A 12-Week Extension Study looking at the effects of Lurasidone (SM-13496) in Subjects with SchizophreniaMedDRA version: 20.0 Level: PT Classification code 10039626 Term: Schizophrenia System Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2016-000061-23-SKSunovion Pharmaceuticals Inc.283
已完成
3 期
Lurasidone - A 24-week Extension Study of Patients With Bipolar I DepressionBipolar DepressionNCT00868959Sumitomo Pharma America, Inc.817